Groupe la Francaise Has $3.61 Million Stock Position in Johnson & Johnson $JNJ

Key Points

• Groupe la Francaise reduced its stake in Johnson & Johnson by 53.6%, now holding 22,404 shares valued at about $3.61 million after selling over 25,000 shares in the first quarter.
• Several hedge funds increased their holdings in Johnson & Johnson, with Highline Wealth Partners LLC raising its position by 51.8%, reflecting ongoing interest from institutional investors.
• Analysts have set new price targets for Johnson & Johnson, with Barclays, Citigroup, and UBS all raising their target prices, indicating strong market confidence despite a mixed rating outlook.

Groupe la Francaise trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 53.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 22,404 shares of the company's stock after selling 25,851 shares during the period. Groupe la Francaise's holdings in Johnson & Johnson were worth $3,609,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Highline Wealth Partners LLC raised its holdings in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the 1st quarter worth $47,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson in the 1st quarter worth $49,000. Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson in the 1st quarter worth $52,000. Finally, Capital A Wealth Management LLC acquired a new stake in Johnson & Johnson in the 4th quarter worth $50,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Ratings Changes

A number of research firms have commented on JNJ. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Barclays boosted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Finally, Guggenheim reissued a "neutral" rating and set a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $176.29.

Johnson & Johnson Stock Down 0.4%

Shares of Johnson & Johnson stock traded down $0.76 on Monday, hitting $178.53. The company had a trading volume of 6,225,003 shares, compared to its average volume of 8,657,504. The firm has a market capitalization of $429.96 billion, a P/E ratio of 19.09, a P/E/G ratio of 2.28 and a beta of 0.41. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock has a 50-day moving average of $163.95 and a 200-day moving average of $159.48.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.